The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Ryan Arthur F since 2015.
This trader's CIK number is 1187443.
At the time of last reporting, Ryan Arthur F was the Director of Regeneron Pharmaceuticals, Inc.. (stock ticker symbol REGN).
Also see all insider trading activities at Regeneron Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | REGN | 0 | $0 | 100 | $78,150 | 0 | $0 |
| 2024 | REGN | 0 | $0 | 800 | $816,423 | 0 | $0 |
| 2023 | REGN | 0 | $0 | 1,000 | $771,518 | 0 | $0 |
| 2022 | REGN | 0 | $0 | 10,953 | $6,815,391 | 10,453 | $4,312,730 |
| 2021 | REGN | 0 | $0 | 700 | $409,621 | 0 | $0 |
| 2020 | REGN | 0 | $0 | 51,124 | $28,091,415 | 50,124 | $18,000,731 |
| 2016 | REGN | 0 | $0 | 3,000 | $1,255,320 | 0 | $0 |
| 2015 | REGN | 0 | $0 | 29,250 | $12,373,686 | 29,250 | $3,963,521 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-02-09 | REGN | Sale | 100 | 781.50 | 78,150 |
| 2024-10-01 | REGN | Sale | 100 | 1,049.73 | 104,972 |
| 2024-09-03 | REGN | Sale | 100 | 1,179.76 | 117,975 |
| 2024-08-01 | REGN | Sale | 99 | 1,081.77 | 107,095 |
| 2024-08-01 | REGN | Sale | 1 | 1,100.03 | 1,100 |
| 2024-07-01 | REGN | Sale | 100 | 1,059.06 | 105,906 |
| 2024-05-01 | REGN | Sale | 100 | 901.47 | 90,146 |
| 2024-04-01 | REGN | Sale | 100 | 961.56 | 96,156 |
| 2024-03-01 | REGN | Sale | 100 | 978.23 | 97,823 |
| 2024-02-01 | REGN | Sale | 100 | 952.51 | 95,250 |
| 2023-12-01 | REGN | Sale | 100 | 818.55 | 81,854 |
| 2023-11-07 | REGN | Sale | 100 | 828.90 | 82,889 |
| 2023-08-01 | REGN | Sale | 100 | 737.75 | 73,774 |
| 2023-07-03 | REGN | Sale | 100 | 715.83 | 71,582 |
| 2023-06-01 | REGN | Sale | 100 | 734.44 | 73,443 |
| 2023-06-01 | REGN | Sale | 100 | 734.44 | 73,443 |
| 2023-05-01 | REGN | Sale | 100 | 805.46 | 80,546 |
| 2023-04-03 | REGN | Sale | 100 | 819.99 | 81,998 |
| 2023-03-01 | REGN | Sale | 100 | 762.44 | 76,244 |
| 2023-02-01 | REGN | Sale | 100 | 757.46 | 75,745 |
| 2022-08-04 | REGN | Option Ex | 10,453 | 412.58 | 4,312,730 |
| 2022-08-04 | REGN | Sale | 10,453 | 621.48 | 6,496,361 |
| 2022-05-02 | REGN | Sale | 100 | 650.58 | 65,058 |
| 2022-04-01 | REGN | Sale | 100 | 693.17 | 69,316 |
| 2022-03-01 | REGN | Sale | 100 | 615.47 | 61,547 |
| 2022-02-01 | REGN | Sale | 100 | 606.04 | 60,603 |
| 2022-01-03 | REGN | Sale | 100 | 625.07 | 62,506 |
| 2021-12-01 | REGN | Sale | 100 | 636.48 | 63,647 |
| 2021-11-01 | REGN | Sale | 100 | 642.92 | 64,292 |
| 2021-10-01 | REGN | Sale | 100 | 569.44 | 56,944 |
| 2021-09-01 | REGN | Sale | 100 | 678.55 | 67,855 |
| 2021-08-02 | REGN | Sale | 100 | 576.48 | 57,648 |
| 2021-02-01 | REGN | Sale | 100 | 507.82 | 50,781 |
| 2021-01-04 | REGN | Sale | 100 | 484.54 | 48,454 |
| 2020-12-01 | REGN | Sale | 100 | 520.00 | 51,999 |
| 2020-11-02 | REGN | Sale | 100 | 548.92 | 54,891 |
| 2020-10-01 | REGN | Sale | 100 | 559.51 | 55,951 |
| 2020-09-01 | REGN | Sale | 100 | 603.76 | 60,375 |
| 2020-08-03 | REGN | Sale | 100 | 640.50 | 64,049 |
| 2020-07-01 | REGN | Sale | 100 | 612.44 | 61,244 |
| 2020-06-01 | REGN | Sale | 100 | 603.00 | 60,299 |
| 2020-05-06 | REGN | Option Ex | 50,124 | 359.12 | 18,000,731 |
| 2020-05-06 | REGN | Sale | 50,124 | 549.34 | 27,535,168 |
| 2020-05-01 | REGN | Sale | 100 | 522.39 | 52,239 |
| 2020-03-30 | REGN | Sale | 100 | 465.94 | 46,594 |
| 2020-04-01 | REGN | Sale | 100 | 486.06 | 48,606 |
| 2016-11-15 | REGN | Sale | 2,000 | 429.34 | 858,680 |
| 2016-05-24 | REGN | Sale | 1,000 | 396.64 | 396,640 |
| 2015-02-20 | REGN | Option Ex | 29,250 | 135.50 | 3,963,521 |
| 2015-02-20 | REGN | Sale | 29,250 | 423.03 | 12,373,686 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Ryan Arthur F (Director of Regeneron Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.